We answer our clients’ burning questions about gene therapies, including how they work, whether or not they’re safe, and if we’ll see more in the future.

Gene modification and cellular therapies are unique, potentially curative treatments that leverage gene-altering technology

Recent research suggests that the number of gene therapies on the market is likely to increase to over 60 by 2030. As rapid advancements in the field continue, here is what plan sponsors can expect to...

Innovative solution provides $0 member cost for costly specialty drugs while reducing plans’ costs

As the number of approved gene and cellular therapies grows, you can start preparing your organization now by taking the right next steps.

Biosimilars, gene and cell therapies, and cancer drugs are filling the specialty pipeline. Here are some insights for each category to help you stay informed. This topic was the focus of a breakout...

Patients getting access to expensive gene therapies is just one of the many challenges to bringing these sometimes life-saving drugs to market.

Accelerating the progress of biosimilars is key to lowering drug costs and improving patient access to potentially life-saving therapies.

An integrated approach to managing medically billed specialty drugs is key to optimizing cost savings and clinical outcomes.

Getting the most value out of your specialty drug management partner starts with asking the right questions.